And the expression levels of serum HMGB1 and IDO in ESCC patients in clinical stage III-IV were significantly higher than those in stage I-II (P<0.001) (Figures 1D, E). This evidence concerns the gene HMGB1 and esophageal squamous cell carcinoma.